Dermatology Advisor12h
Risankizumab May Be Superior to Other Biologic Therapies in Plaque Psoriasis
Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.
Healio13d
Positive results showcase icotrokinra’s ‘unique’ mechanism of action in plaque psoriasis
Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, ...
TipRanks on MSN16d
InnoCare Pharma Presents Promising Phase II Data for Psoriasis Drug
InnoCare Pharma Ltd. ( ($HK:9969) ) just unveiled an update. InnoCare Pharma Ltd. announced the successful presentation of phase II clinical data ...
Medscape8d
Significant Improvement in Psoriasis Observed With Novel Oral Drug Icotrokinra, in Phase 3 Trial
Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...
PMLive14d
J&J/Protagonist’s icotrokinra shows promise in phase 3 plaque psoriasis programme
Results from the phase 3 ICONIC-LEAD study presented at this year’s American Academy of Dermatology (AAD) annual meeting showed that the candidate, icotrokinra (JNJ-2113), was associated with ...